Beyond Antibiotics: What the Future Holds
The prevalence of multidrug resistance (MDR) and stagnant drug-development pipelines have led to the rapid rise of hard-to-treat antibiotic-resistant bacterial infections. These infectious diseases are no longer just nosocomial but are also becoming community-acquired. The spread of MDR has reached...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-09-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/13/10/919 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850205997033848832 |
|---|---|
| author | Payam Benyamini |
| author_facet | Payam Benyamini |
| author_sort | Payam Benyamini |
| collection | DOAJ |
| description | The prevalence of multidrug resistance (MDR) and stagnant drug-development pipelines have led to the rapid rise of hard-to-treat antibiotic-resistant bacterial infections. These infectious diseases are no longer just nosocomial but are also becoming community-acquired. The spread of MDR has reached a crisis level that needs immediate attention. The landmark O’Neill report projects that by 2050, mortality rates associated with MDR bacterial infections will surpass mortality rates associated with individuals afflicted with cancer. Since conventional antimicrobials are no longer very reliable, it is of great importance to investigate different strategies to combat these life-threatening infectious diseases. Here, we provide an overview of recent advances in viable alternative treatment strategies mainly targeting a pathogen’s virulence capability rather than viability. Topics include small molecule and immune inhibition of virulence factors, quorum sensing (QS) quenching, inhibition of biofilm development, bacteriophage-mediated therapy, and manipulation of an individual’s macroflora to combat MDR bacterial infections. |
| format | Article |
| id | doaj-art-e7d633ed14904ba7a199708bfbb098b4 |
| institution | OA Journals |
| issn | 2079-6382 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj-art-e7d633ed14904ba7a199708bfbb098b42025-08-20T02:10:57ZengMDPI AGAntibiotics2079-63822024-09-01131091910.3390/antibiotics13100919Beyond Antibiotics: What the Future HoldsPayam Benyamini0Department of Health Sciences at Extension, University of California Los Angeles, 1145 Gayley Ave., Los Angeles, CA 90024, USAThe prevalence of multidrug resistance (MDR) and stagnant drug-development pipelines have led to the rapid rise of hard-to-treat antibiotic-resistant bacterial infections. These infectious diseases are no longer just nosocomial but are also becoming community-acquired. The spread of MDR has reached a crisis level that needs immediate attention. The landmark O’Neill report projects that by 2050, mortality rates associated with MDR bacterial infections will surpass mortality rates associated with individuals afflicted with cancer. Since conventional antimicrobials are no longer very reliable, it is of great importance to investigate different strategies to combat these life-threatening infectious diseases. Here, we provide an overview of recent advances in viable alternative treatment strategies mainly targeting a pathogen’s virulence capability rather than viability. Topics include small molecule and immune inhibition of virulence factors, quorum sensing (QS) quenching, inhibition of biofilm development, bacteriophage-mediated therapy, and manipulation of an individual’s macroflora to combat MDR bacterial infections.https://www.mdpi.com/2079-6382/13/10/919phage therapypilicidesquorum sensing and biofilm inhibitorstoxoidsmicrofloral transplantstype III secretion system inhibitors |
| spellingShingle | Payam Benyamini Beyond Antibiotics: What the Future Holds Antibiotics phage therapy pilicides quorum sensing and biofilm inhibitors toxoids microfloral transplants type III secretion system inhibitors |
| title | Beyond Antibiotics: What the Future Holds |
| title_full | Beyond Antibiotics: What the Future Holds |
| title_fullStr | Beyond Antibiotics: What the Future Holds |
| title_full_unstemmed | Beyond Antibiotics: What the Future Holds |
| title_short | Beyond Antibiotics: What the Future Holds |
| title_sort | beyond antibiotics what the future holds |
| topic | phage therapy pilicides quorum sensing and biofilm inhibitors toxoids microfloral transplants type III secretion system inhibitors |
| url | https://www.mdpi.com/2079-6382/13/10/919 |
| work_keys_str_mv | AT payambenyamini beyondantibioticswhatthefutureholds |